Industry News
Biotechnology Industry News
Cortexyme shakes things up with Novosteo acquisition, leadership change and a new name
Cortexyme shakes things up with Novosteo acquisition, leadership change and a new name gmasson Tue, 05/10/2022 - 10:26
Starting gun? $11.6B M&A domino falls as Pfizer scoops up Biohaven for phase 3 migraine nasal spray
Starting gun? $11.6B M&A domino falls as Pfizer scoops up Biohaven for phase 3 migraine nasal spray mbayer Tue, 05/10/2022 - 09:25
Adimab swaps scientist for lawyer as CEO Tillman Gerngross steps down after 15 years
Adimab swaps scientist for lawyer as CEO Tillman Gerngross steps down after 15 years jwaldron Tue, 05/10/2022 - 08:38
Moneybags Nuvation deprioritizes 2 solid tumor prospects to narrow focus onto 3 candidates
Moneybags Nuvation deprioritizes 2 solid tumor prospects to narrow focus onto 3 candidates ntaylor Tue, 05/10/2022 - 08:23
Idorsia drug fails to quell binge eating in midphase trial, driving biotech to abandon the indication
Idorsia drug fails to quell binge eating in midphase trial, driving biotech to abandon the indication ntaylor Tue, 05/10/2022 - 06:26
Eisai wraps filing for Biogen-partnered Aduhelm followup, hoping to regain ‘credibility and trust’
Eisai wraps filing for Biogen-partnered Aduhelm followup, hoping to regain 'credibility and trust' aarmstrong Mon, 05/09/2022 - 15:54
Eisai wraps filing for Biogen-partnered Aduhelm follow-up, hoping to regain ‘credibility and trust’
Eisai wraps filing for Biogen-partnered Aduhelm follow-up, hoping to regain 'credibility and trust' aarmstrong Mon, 05/09/2022 - 15:54
More Moma: $150M series B will push precision cancer drugs to clinic by 2024
More Moma: $150M series B will push precision cancer drugs to clinic by 2024 gmasson Mon, 05/09/2022 - 15:13
Sesen Bio reports progress with regulators as it preps for new cancer trial, but issues remain
Sesen Bio reports progress with regulators as it preps for new cancer trial, but issues remain mbayer Mon, 05/09/2022 - 11:01
Investors take root in Aspen Neuroscience’s customized cell therapy as $147.5M round closes
Investors take root in Aspen Neuroscience’s customized cell therapy as $147.5M round closes gmasson Mon, 05/09/2022 - 10:45
LogicBio’s sun and shares rise again after FDA releases clinical hold on pediatric genome editing therapy
LogicBio's sun and shares rise again after FDA releases clinical hold on pediatric genome editing therapy aarmstrong Mon, 05/09/2022 - 10:11
J&J axes Bavarian Nordic pact for HPV and Hep B vax, keeps two other programs
J&J axes Bavarian Nordic pact for HPV and Hep B vax, keeps two other programs mbayer Mon, 05/09/2022 - 09:53
J&J axes Bavarian Nordic pact for HPV and hep B vax, keeps 2 other programs
J&J axes Bavarian Nordic pact for HPV and hep B vax, keeps 2 other programs mbayer Mon, 05/09/2022 - 09:53
Investors flip-flop on Nykode’s cancer vaccine data drop
Investors flip-flop on Nykode's cancer vaccine data drop ntaylor Mon, 05/09/2022 - 06:36
Another Oxurion eye disease drug flunks phase 2, leaving biotech all-in on last prospect
Another Oxurion eye disease drug flunks phase 2, leaving biotech all-in on last prospect ntaylor Mon, 05/09/2022 - 05:31
UPDATE: VistaGen says regulators couldn’t sniff out abuse potential of its nasal spray for social anxiety
UPDATE: VistaGen says regulators couldn’t sniff out abuse potential of its nasal spray for social anxiety mbayer Fri, 05/06/2022 - 10:32
With Sarepta in its sights, PepGen prices IPO to fund DMD trials
With Sarepta in its sights, PepGen prices IPO to fund DMD trials ntaylor Fri, 05/06/2022 - 07:16
Bye-bye: Xencor culls 2 bispecifics after early-phase solid tumor data underwhelm
Bye-bye: Xencor culls 2 bispecifics after early-phase solid tumor data underwhelm ntaylor Fri, 05/06/2022 - 06:14
Orion aims to challenge Vertex with new pain management licensing deal
Orion aims to challenge Vertex with new pain management licensing deal jwaldron Fri, 05/06/2022 - 06:02
After layoffs, BridgeBio turns to dealmaking for up to 6 drugs
After layoffs, BridgeBio turns to dealmaking for up to 6 drugs gmasson Thu, 05/05/2022 - 14:20